Related content

Risk Factors for Severe Adverse Effects and Treatment-related Deaths in Japanese Patients Treated with Irinotecan-based Chemotherapy: A Postmarketing Survey †

By Shiozawa Tomoo   Tadokoro Jun-ichi   Fujiki Toshitaka   Fujino Koji   Kakihata Koji   Masatani Shuji   Morita Satoshi   Gemma Akihiko   Boku Narikazu  

Japanese Journal of Clinical Oncology, Vol. 43, Iss. 5, 2013-05 ,pp. : 483-491

Oxford University Press

Access to resources Recommend Favorite

A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer

By Han Ji-Youn   Lee Dae   Lee Sung   Park Chun   Kim Hae   Kim Eun-A   Yoon Sung   Lee Hong   Lee Jin  

Medical Oncology, Vol. 22, Iss. 3, 2005-09 ,pp. : 281-290

Humana Press, Inc

Access to resources Recommend Favorite

Excess Toxicity Associated with Docetaxel and Irinotecan in Patients with Metastatic, Gemcitabine-Refractory Pancreatic Cancer: Results of a Phase II Study

By Ko Andrew   Dito Elizabeth   Schillinger Brian   Venook Alan   Bergsland Emily   Tempero Margaret  

Cancer Investigation, Vol. 26, Iss. 1, 2007-12 ,pp. : 47-52

Informa Healthcare

Access to resources Recommend Favorite

The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you?

By Lau Phyllis  

Supportive Care in Cancer, Vol. 12, Iss. 9, 2004-09 ,pp. : 626-633

Springer Publishing Company

Access to resources Recommend Favorite

Health-related quality of life in patients with advanced colorectal cancer: results from a phase II study of S-1 combined with irinotecan (CPT-11)

By Tsunoda Akira   Yasuda Naokuni   Nakao Kentaro   Narita Kazuhiro   Watanabe Makoto   Matsui Nobuaki   Tsunoda Yuko   Kusano Mitsuo  

International Journal of Clinical Oncology, Vol. 15, Iss. 3, 2010-06 ,pp. : 280-286

Springer Publishing Company

Access to resources Recommend Favorite